Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
PARIS and CAMBRIDGE, Mass., Oct. 04, 2017 -- Lysogene (FR0013233475 – LYS) (LYS.PA), a leading, biopharmaceutical company pioneering gene therapy technologies to treat central nervous system diseases, today announced that it will be participating in the following investor events in the upcoming weeks:
| October | |||
| |||
| Date: | Wednesday, October 11 | ||
| Time | 3:45pm Eastern Time | ||
| Location: | Westin New York Grand Central, Assembly Room | ||
| |||
| Date: | Thursday, October 12 | ||
| Time: | 2:30pm Eastern Time | ||
| Location: | Westin New York Grand Central | ||
| |||
| Date: | Friday, October 13 | ||
| Time: | 12:00pm – 1:30pm Eastern Time | ||
| Location | Lotte New York Palace Hotel | ||
| Webcast: http://lifesci.rampard.com/20171013/reg.jsp | |||
| November | |||
| |||
| Date: | Tuesday, November 14 & Wednesday, November 15 | ||
| Time: | TBD | ||
| Location | Waldorf Hilton | ||
About Lysogene
Lysogene (www.lysogene.com) is a global biopharma leader in orphan CNS disease research and development. Lysogene has generated five non-cumulative years of clinical safety data to show the efficiency of a direct delivery route to the CNS with its initial gene therapy trial for MPS IIIA. Lysogene has recently completed the enrollment for the first multi-national observational study in MPS IIIA which will function as the non-concurrent control for the first pivotal trial for MPS IIIA in H1 2018. Lysogene also plans a clinical trial for GM1 Gangliosidosis for 2019. Lysogene has obtained orphan drug designation from the EMA and FDA and rare pediatric designation by the FDA for both programs.
Lysogene is listed on the Euronext regulated market in Paris (ISIN code: FR0013233475).
For more information: www.lysogene.com.
Contacts
| Media: | Investors: | |
| Europe | ||
| Annie-Florence Loyer | Chris Maggos | |
| NewCap | LifeSci Advisors | |
| [email protected] | [email protected] | |
| + 33 6 88 20 35 59 | +41 79 367 6254 | |
| + 33 1 44 71 00 12 | ||
| North America | ||
| Marion Janic | ||
| RooneyPartners | ||
| [email protected] | ||
| + 1 (212) 223-4017 |
